4/13/2020 5:01:41 AM
ASLAN Temporarily Pauses Recruitment Of New Patients Into ASLAN004 Study
3/18/2020 5:37:51 AM
ASLAN Pharmaceuticals Q4 Net Loss $29.6 Mln Vs Loss $11.2 Mln Last Year
12/3/2019 1:06:01 AM
ASLAN Pharma Prices Public Offering Of 5.12 Mln ADSs At $2.50/ADS
10/22/2019 2:53:44 AM
ASLAN Pharma Enrolls First Patient In Proof-of-Concept Study For ASLAN004 Targeting Atopic Dermatitis
10/2/2019 2:58:29 AM
ASLAN Presents New Data On Varlitinib At ESMO 2019
7/26/2019 4:48:10 AM
ASLAN Pharma Elects Andrew Howden As Non-executive Chairman; Carl Firth To Continue To Serve As CEO
3/29/2019 6:06:00 AM
ASLAN Pharma Completes First Part Of Single Ascending Dose Study For ASLAN004 Targeting Atopic Dermatitis
3/22/2019 7:45:48 AM
ASLAN Pharma Q4 Net Loss $11.2 Mln Vs Loss $14.5 Mln Last Year
1/23/2019 1:35:44 AM
ASLAN Announces Publication Of New Pre-Clinical Data Demonstrating The Activity Of Varlitinib In TNBC Cell Lines
1/4/2019 2:03:24 AM
ASLAN Announces IND Submission For ASLAN003 To U.S. FDA And Conclusion Of 30-Day Review Period